Two isoforms of DNA topoisomerase II (topo II) have been identified in mammalian cells. While topo II␣ is essential for chromosome segregation in mitotic cells, in vivo function of topo II␤ remains to be clarified. Here we demonstrate that the nucleoplasmic topo II␤, highly expressed in differentiating cerebellar neurons, is the catalytically competent entity operating directly on chromatin DNA in vivo. When the cells reached terminal differentiation, this in vivo activity decreased to a negligible level with concomitant loss of the nucleoplasmic enzyme. Effects of topo II-specific inhibitors were analyzed in a primary culture of cerebellar granule neurons that can mimic the in vivo situation. Only the ␤ isoform was expressed in granule cells differentiating in vitro. ICRF-193, a catalytic topo II inhibitor, suppressed the transcriptional induction of amphiphysin I which is essential for mature neuronal activity. The effect decreased significantly as the cells differentiate. Expression profiling with a cDNA macroarray showed that 18% of detectable transcripts were up-regulated during the differentiation and one-third of them were susceptible to ICRF-193. The results suggest that topo II␤ is involved in an early stage of granule cell differentiation by potentiating inducible neuronal genes to become transcribable probably through alterations in higher order chromatin structure.
DNA topoisomerase II (topo II)
1 is essential for cell proliferation since some mitotic events such as condensation and segregation of daughter chromosomes are entirely dependent on its activity. It is also likely to be involved in other DNA transactions like DNA replication, transcription, and recombination (1) . The enzyme, in a heart-shaped dimer form (2) , catalyzes topological transformations of DNA by transient cleavage of DNA double strands forming an enzyme-operated gate, followed by passing a second double-stranded DNA segment through the gate (3, 4) . Only one form of topo II is present in lower eukaryotes and invertebrates whereas in mammalian cells two isoforms, the 170-kDa topo II␣ and the 180-kDa topo II␤, that are encoded by separate genes have been identified (5) (6) (7) . These isoforms may share their roles in different cellular functions although they show similar catalytic properties in vitro. From the following observations, topo II␣ is considered to be the main isoform involved in the mitotic processes. First, there is a positive correlation between the cellular concentration of topo II␣ and the rate of cell proliferation (8, 9) . Second, the expression of mRNA for topo II␣ is higher in tissues containing proliferating cells (10) and is localized in brain regions enriched with mitotic cells (11, 12) . Third, the level of topo II␣ protein peaks at G 2 /M phase during the cell cycle (9, 13) and finally, high affinity binding of topo II␣ with chromatin at mitosis is essential for chromosome condensation/segregation and topo II␤ cannot be substituted for topo II␣ (14) .
In contrast to topo II␣, functional aspect of topo II␤ remains obscure (1, 15) . Our previous studies demonstrated a significant level of topo II activity in isolated nuclei from post-mitotic neuronal cells (16, 17) , that was shown later to be attributable to the ␤ isoform (11) . Expression of topo II␤ was also shown in other nonproliferative or fully differentiated tissues at both the transcript (10) and the protein levels (18, 19) . Cell cycle analysis in cultured cells showed that the level of topo II␤ was not altered significantly and, in a sharp contrast to topo II␣, it rather increased slightly as cells reached a plateau phase (9, 13, 20) . Expression of topo II␤ in these immortalized cell lines, however, is probably deregulated. Topo II␤ is even dispensable for cell proliferation and survival in vitro since in some cell lines the enzyme is not expressed at all (21) . These observations suggest that topo II␤ is not required for maintenance of general cellular activities but rather involved in more specific processes in vivo.
The cerebellar cortex has a unique structure with laminar arrangement of cells that is formed during the development in early postnatal period. A number of mRNAs were identified to be expressed specifically at distinct stages of cerebellar development (22, 23) . We have shown previously using in situ hybridization that in the first two postnatal weeks the signal levels for topo II␤ mRNA increased on the cerebellar granule cells actively differentiating in the granular layer, suggesting a link between the topo II␤ expression and the cerebellar development (12) . The cerebellar system also appears to be ideal in elucidating the physiological function of topo II␤ since the control of its expression in cultured cell lines may well be aberrant. Parenthetically, there have been no detailed studies on temporo-spatial expression of topo II isoforms in living tissues. In the present study, we discriminated the catalytically competent entity of topo II isoforms that is acting on chromatin DNA in the developing cerebellar tissue. Postnatal expression levels and intranuclear localization of topo II␤ were also traced in the cerebellar neuronal lineages, Purkinje cells and granule cells. We finally assessed the requirement of topo II␤ activity in the expression of neuronal genes in a primary culture of differentiating granule cells by use of topo II-specific inhibitors. Our results are consistent with the defects in embryonic neural development identified recently in topo II␤ knockout mice (24) .
EXPERIMENTAL PROCEDURES

Antibodies
Topoisomerase II␣-Full-length cDNA for human topo II␣ was expressed in Escherichia coli, and mice were immunized with purified protein to prepare monoclonal antibodies as described previously (25) . One of the isolated clones, 4E12, recognized a NH 2 -terminal fragment (residues numbers 1-40), and was cross-reactive to rodent topo II␣ (26) .
Topoisomerase II␤-Full-length cDNA for human topo II␤ was expressed and mouse monoclonal antibodies were prepared as above. One of the isolated clones, 3B6, was also reactive to rodent topo II␤ (26) , recognizing a COOH-terminal fragment (residues numbers 1178 -1273).
Amphiphysin I-IgG was purified from the serum of a breast cancer patient with anti-amphiphysin I autoantibodies and paraneoplastic sensory neuropathy (27) .
Neurofilament-A mouse monoclonal antibody to the rat neurofilament proteins (160 K/210 K) was purchased from IBL (Gunma, Japan).
Western Blot Analysis
Nuclei were prepared from cerebellum, cerebral cortex, and thymus of male Wistar rats as described previously (28) . Nuclear samples were pretreated with 50 g/ml DNase I at room temperature for 30 min prior to electrophoresis. Topo II-enriched fraction was extracted from the purified nuclei with 20 mM Tris-HCl (pH 7.5), 0.3 M NaCl, and 140 mM 2-mercaptoethanol. Cultured granule cells were directly lyzed in the loading buffer with a brief sonication. Samples were heated at 95°C for 1 min in a loading buffer and then subjected to SDS-polyacrylamide gel electrophoresis. Separated proteins in gels were transferred to nitrocellulose membranes by electroblotting and processed for immunodetection according to a standard procedure. Secondary antibodies were peroxidase-conjugated goat antibodies (Bio-Rad) and the peroxidase activity was visualized with 4-methoxy-1-naphthol and hydrogen peroxide.
Immunohistochemical Detection
Male Wistar rats under deep anesthesia were perfused transcardially with 0.9% saline, followed by 4% paraformaldehyde and 0.2% picric acid in 100 mM sodium phosphate (pH 7.4). The brain was dissected out, post-fixed with the same solution, and cryoprotected with 20% sucrose in 100 mM sodium phosphate (pH 7.4). After trimming, the brain blocks were frozen rapidly and sectioned at a thickness of 10 m on a cryostat.
Frozen sagittal sections were thaw-mounted on glass slides precoated with 3-aminopropyltriethoxysilane, followed by washing with PBS (150 mM NaCl in 10 mM sodium phosphate, pH 7.4), blocking with PBS containing 10% goat serum and 0.3% Triton X-100, and incubation for 15 h with primary antibodies diluted in PBS containing 0.3% Triton X-100 (TPBS). The incubation was performed either at 37°C (monoclonal antibodies against topo II isoforms) or at room temperature (all the other antibodies). After washing with TPBS, the sections were incubated successively at room temperature with biotinylated goat secondary antibodies (Vector Labs) and with the ABC reagent (Vectastain ABC Kit, Vector Labs). The peroxidase reaction was visualized with diaminobenzidine and hydrogen peroxide.
Cultured granule cells that were grown on coverslips precoated with poly-L-lysine were fixed with 4% paraformaldehyde in PBS at room temperature for 15 min. The fixed cells were immunostained as described above for tissue sections.
Immunofluorescence Microscopy and Confocal Microscopy
The brain tissue was perfused as described above except that the solution did not contain picric acid. Frozen sagittal sections (14 m) were mounted on glass slides as mentioned, washed with PBS, permeabilized with 0.3% Triton X-100 in PBS, and blocked with 10% goat serum and 10% horse serum in TPBS. After incubation with various primary antibodies diluted in TPBS containing 3% horse serum for 15 h, sections were washed with PBS, followed by incubation with fluorescent conjugates of goat secondary antibodies in PBS at room temperature for 30 min. DNA was then stained with 0.25 g/ml 4Ј,6-diamidino-2-phenylindole in PBS. Stained sections were mounted in an antifade solution (Prolong Antifade Kit, Molecular Probes, Eugene, OR) and examined under an OLYMPUS epifluorescence microscope (BX60-FLB) coupled to a cooled monochromatic CCD camera (Hamamatsu Photonics) or OLYMPUS laser scanning microscope (FLUOVIEW-BX50). Recorded digital images were processed later using Adobe Photoshop software.
Determination of Topoisomerase Activities in Vivo
From male Wistar rats of P10, the cerebellum was dissected out under deep anesthesia and immediately cut into 1-mm thick slices on ice (about 10 sagittal slices), submerged in 1 ml of RPMI 1640 with or without 100 M etoposide, and incubated at 37°C for 2 h in a CO 2 incubator. The slices were homogenized with 3 ml of 1% (v/v) Sarkosyl in 10 mM Tris-HCl (pH 7.5) and 1 mM EDTA (TE buffer), and then fractionated by centrifugation on a CsCl step gradient (2-ml layers of CsCl solutions in TE buffer with densities of 1.82, 1.72, 1.50, and 1.37 g/cm 3 ) according to Muller and Mehta (29) . Density of the gradient fractions (0.5 ml) was calculated from the refractive index of each fraction. DNA concentration was estimated by a spectrophotometric method based on the Warburg-Christian equation. Aliquots (47 l for topo II␣ detection and 12 l for topo II␤ detection) of each fraction were diluted 1:3 with TE buffer and blotted onto nitrocellulose membranes using a slot blotting apparatus (Bio-Dot SF, Bio-Rad). The membranes were then processed for immunostaining with topo II isoform-specific monoclonal antibodies according to the procedure described above. Stains on the membrane were scanned on a scanner and topo II isoforms in each fraction were quantified using a densitometric software, Intelligent Quantifier (Bio Image).
Primary Culture
Cerebellar granule cells were prepared from the cerebellum of P8 Wistar rats and processed for culture as described previously (30) . The tissue was treated briefly with trypsin and DNase I and the dispersed cells were cultured at 37°C in a humidified atmosphere of 5% CO 2 in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 25 mM KCl, and 60 g/ml kanamycin sulfate. The cell suspension from one cerebellum was dispensed into 6 plastic culture dishes (60 mm in diameter) precoated with poly-L-lysine. After 24 h in culture, proliferation of non-neuronal cells was prevented by replacing the medium with that containing 10 M cytosine arabinoside. The medium was refreshed at the end of day 3. Cells remained viable under these conditions for at least 8 days in culture.
Northern Blot Analysis
Total cellular RNA was prepared from the cultured cells by using a commercial kit (RNeasy, Quiagen). RNA samples (17 g/lane) were electrophoresed and blotted as described previously (11) . cDNA clones encoding the neuronal markers (amphiphysin I, amphiphysin II, synaptophysin, and ␥-aminobutyric acid receptor ␣6) were first obtained by polymerase chain reaction amplification of a rat brain cDNA library (Uni-Zap XR, Stratagene) with unique primer sets designed to amplify 500 -1500-base pair regions of the cDNAs. Products were cloned into the pGEM-T vector (Promega) and verified by nucleotide sequencing. Hybridization probes were prepared by polymerase chain reaction amplification of the cloned cDNA fragments with the same primer sets. The purified products were labeled by a random-primed synthesis with [␣-32 P]dCTP. Hybridization was carried out under standard conditions at 42°C overnight in a solution containing 50% (v/v) formamide.
mRNA Expression Profiling
A cDNA macroarray system (Atlas Rat 1.2 Array, Clontec) was used for determination of relative levels of mRNAs that are expressed in granule neurons differentiating in vitro. Total cellular RNA was isolated from untreated granule cells at day 1, at day 5, and ICRF-treated cells at day 5 as described above. The following procedures were performed according to the protocol supplied by the manufacturer. Briefly, RNA preparations were first treated with DNase I, followed by enrichment of poly(A) ϩ RNA on streptoavidin magnetic beads. RNA templates bound to the beads were subjected to cDNA synthesis with rat CDS primer mixture and [␣-32 P]dATP. Purified cDNA probes (Ͼ6.5 ϫ 10 6 cpm) were hybridized to the arrayed rat cDNA membranes under recommended conditions. Washed membranes were exposed against the imaging plate for 12 h at room temperature and hybridization signals were quantified on the BAS 2000 analyzer using an array-analysis software ArrayGauge (Fuji Film).
RESULTS
Expression of DNA Topoisomerase II Isoforms in Rat
Cerebellar Cortex at Postnatal Day 10 (P10)-As we have shown previously, mRNAs of both topo II␣ and topo II␤ were detected by in situ hybridization in the P10 rat cerebellum (11) . To confirm the expression of these enzymes at the protein level, nuclei isolated from rat tissues were first subjected to Western blot analysis. A monoclonal antibody, 3B6, raised against human topo II␤ specifically recognized a 180-kDa polypeptide in rat cerebellum (Fig. 1, lane 5) . A band with the same mobility was also detected in cerebral cortex (lane 6) but not in P14 rat thymus (lane 4) unless the color development was prolonged. In contrast to topo II␤, Western blot signals were quite low when total nuclear proteins were probed with a monoclonal antibody, 4E12, raised against human topo II␣. However, when nuclear salt extracts enriched with topo II were used for the analysis, the antibody detected an immunoreactive band of 170 kDa, the molecular mass expected for canonical topo II␣, in both thymus and cerebellum (Fig. 1, lanes 1 and 2) , but still failed to detect any reactive bands in cerebral cortex (lane 3). These results are consistent with the levels of transcripts estimated previously by Northern blot analysis and further support the idea that the expression of topo II␣ is tightly associated with cell proliferation whereas that of topo II␤ is not (11) . These results also confirmed that both isoforms of topo II are expressed in P10 rat cerebellum and that the monoclonal antibodies, 4E12 and 3B6, can be used as a specific probe for topo II␣ and topo II␤, respectively.
Catalytic Activities of DNA Topoisomerase II Isoforms Detected in Vivo during the Postnatal Development of the Cerebellum-The results presented above or simple immunohistochemical detection methods with specific antibodies do not provide information on the abundance of catalytically active topo II molecules. Although it is possible to measure topo II activities in tissue extracts, this in vitro activity on naked DNA does not reflect the topo II enzyme acting on DNA in situ, since their accessibility is largely restricted in vivo by local chromatin structures (31, 32) . The way to circumvent this problem is to take advantage of the unique property of topo II enzymes. A class of topo II inhibitors, sometimes referred to as "topo II poisons," such as etoposide (VP-16) binds specifically to the enzyme and stabilizes the topo II-DNA covalent complex (cleavable complex) by preventing the religation of transiently cleaved DNA strands (33) . Upon addition of strong detergents, the complex is disrupted to liberate DNA fragments with denatured topo II protein covalently attached to the 5Ј termini. For quantitative estimation of functional topo II isoforms in the developing rat cerebellum, cerebellar slices were incubated with etoposide as described under "Experimental Procedures." The tissue was then homogenized in Sarkosyl, and the functioning topo II molecules cross-linked to DNA were separated from the free enzyme by CsCl step gradient centrifugation. Gradient fractions were blotted onto membranes and probed with the monoclonal antibodies to topo II␣ or topo II␤, thus enabling the isoform-specific detection. Fig. 2 shows a representative result obtained with P10 rat cerebellum. When the tissue was incubated in the absence of etoposide, both topo II␣ and topo II␤ were completely recovered in fractions with a density of typical proteins (Fig. 2, A and C) . In the presence of etoposide, however, 55% of topo II␣ and 22% of topo II␤ were recovered in the DNA peak fractions at around 1.69 g/cm 3 ( Fig. 2, B and D) . The immunoreactive material in the DNA peak fractions represents the topo II-DNA complexes accumulated during the incubation with etoposide, and thus reflects an in vivo activity of enzymes that are accessible to chromatin DNA. The density of these complexes is comparable to that of bulk DNA because of the small topo II versus DNA mass ratio. When the lysate DNA was fragmented by sonication before loading the gradient, the peak of topo II-DNA complexes shifted toward the right depending on the extent of sonication and became separated from the DNA peak. By estimating the average length of DNA fragments, it was calculated that under these conditions one or two topo II monomers are cross-linked to a few kilobase pairs of DNA.
In rodents, the gross organization of cerebellar tissue initiates after birth and is completed within 3 weeks. During this period, the precursor for granule cells, the most abundant neurons in central nervous system, proliferate in the outmost layer (external germinal layer, EGL), then migrate inward through the molecular layer and the Purkinje cell layer to form the granular layer, where they continue to differentiate establishing neuronal connections (34) . Using the cross-linking technique, we next assessed the in vivo activity of topo II isoforms and their total protein levels during the postnatal development of rat cerebellum (Fig. 3) . The difference in the densitometric levels indicated on the ordinate roughly reflects the relative abundance of topo II isoforms in the cerebellum. Topo II␣ linked to DNA increased rapidly during the first 5 days after birth, reaching a peak at P9, and sharply decreased thereafter in the second week to a negligible level at P20 (Fig. 3A) . More than 50% of topo II␣ was cross-linked to DNA between P5 and P10 when its expression level was also high. At P27, topo II␣ was no longer detectable in both the DNA peak fractions and free protein fractions. On the other hand, topo II␤ showed a triphasic time course during the postnatal development (Fig.  3B) . In both its total amount and the DNA-linked forms, the enzyme gave a high signal already at P1 and after a transient decrease at P5, turned to increase again (second phase). The topo II␤-DNA complex stayed at a high level during the first 2 weeks, decreased gradually in the third week, and became almost undetectable at P27. Interestingly, the peak of granule cell differentiation in the second week coincides with the period when topo II␤ is most active on chromatin. The total amount of topo II␤ was also maintained at an elevated level during the first 2 weeks, then decreased to about half the maximum level at P20, and in contrast to topo II␣, this level was maintained at P27 (third phase) and even in adulthood. The time course of topo II␤ expression was also confirmed by a conventional Western blotting of tissue lysates (Fig. 3B, open triangles) .
To identify what cell populations contribute to the levels of total enzyme and their in vivo activities, spacial distribution of topo II isoforms in the developing cerebellar cortex was visualized by immunostaining (Fig. 4) . The topo II␣-positive cells in 1-3, 30 g of protein/lane) or whole nuclei treated with DNase I (lanes 4 -6, 5 g of protein/lane), were subjected to 6% SDS-polyacrylamide gel electrophoresis and blotted onto a nitrocellulose membrane. Blotted membranes were probed with mouse monoclonal antibodies raised against human topo II␣, 4E12 (lanes 1-3, 2 g of IgG/ml) or human topo II␤, 3B6 (lanes 4 -6, 1 g of IgG/ml). Lanes 1 and 4, P14 rat thymus nuclei; lanes 2 and 5, P10 rat cerebellar nuclei; lanes 3 and 6, P10 rat cerebral cortex nuclei; lane M, molecular weight markers.
EGL were already present at P1, increased in number to peak at P10, and decreased to disappear at P25 (Fig. 4A ). This changing pattern closely parallels the monophasic time course of its in vivo activity (Fig. 3A) , which can thus be ascribed to the granule cell progenitors proliferating in the mitotic zone of EGL. Topo II␣ signal was not detected in Purkinje cells throughout the postnatal period, being consistent with the fact that their final cell division occurs in an embryonic stage. With respect to the in vivo activity of topo II␤ (Fig. 3B) , the initial phase is likely due to the multilayered Purkinje cells that constitute the major population of topo II␤-positive cells at P1 (Fig. 4A) . The fluorescence and confocal microscopy at a higher magnification revealed that both nucleoplasm and nucleolus are brightly stained in P1 Purkinje cells (Fig. 4B) . As they mature, the topo II␤ signal decreased significantly in nucleoplasm but persisted in nucleoli. Granule cells should contribute little to the topo II␤ activity at P1 since its population size is still small and granular layer is not generated yet. However, the second phase of the topo II␤ activity that peaks around P9 is clearly accounted for by the growing population of differentiating granule cells. Granule cell nuclei in the granular layer were highly labeled with anti-topo II␤ antibody at P10 but the signal was attenuated significantly at P25 when granule cells reach maturity (Fig. 4B) . After the completion of cerebellar architecture, there is an intriguing discrepancy between the amount of topo II␤ expressed in nuclei and that actually acting on DNA. At this stage, a large proportion of the enzyme appears to be localized in nucleoli (Fig. 4B) .
Effects of Topo II-specific Inhibitors on the Granule Cells Differentiating in Vitro-
The topographical and chronological analyses on the levels of topo II␤ expression and its in vivo activity suggested that the isoform ␤ may play a critical role in the differentiation process of cerebellar neurons. To further investigate this possibility, we used a primary culture system for cerebellar granule cells that has been well established and used successfully in many studies. Expression of various genes required for neuronal maturation was shown to be tightly regulated in the course of culture, mimicking the in vivo situation (35, 36) .
Granule cells prepared from P8 rat cerebellum by enzymatic dissociation extend processes in vitro to form elaborate neurite networks during the culture as shown by the staining with an antibody against neurofilaments (Fig. 5) . When cells were stained with anti-topo II␣ antibody, only a small proportion of cell nuclei (Ͻ4%) was positive for topo II␣ after 1 day in culture (indicated by arrow). The positive cells decreased further in the following days. This is consistent with the notion that cells surviving in the culture are mostly postmitotic granule neurons. However, the level of topo II␤ expression was already significant on day 1 in a large population of cell nuclei and appeared to increase as the cells differentiate in vitro, resembling the changing profile observed in vivo. The enhanced staining might be caused in part by an increased accessibility of the antibody since only a moderate increase in the levels of topo II␤ protein and its mRNA was observed (data not shown).
Expression of representative genes underlying the differentiation phenotypes of the granule neuron were then analyzed. Amphiphysin I is a protein highly expressed in the central nervous system, including cerebellum, and involved in synaptic membrane recycling at nerve terminals (37) . Levels of amphiphysin I was measured daily by immunoblotting (Fig. 6) . The expression of amphiphysin I was markedly induced during the culture period, up to more than 10 times at day 5 as compared with day 1. However, in the continuous presence of ICRF-193, a topo II-specific inhibitor, the induction was sup- Cerebellar slices from P1 through P27 rats were incubated with or without 100 M etoposide and the DNA-linked topo II was separated from free enzyme by CsCl density gradient centrifugation. Topo II isoforms in the gradient fractions were quantified as in Fig. 2 pressed significantly. Under these conditions topo II␤ activity was inhibited to Ͻ5% of control.
2 Similar effect on the amphiphysin I induction was exerted with etoposide at a noncytotoxic concentration. Although these inhibitors do not discriminate topo II isoforms, one can assume that topo II␤ is the only target of the drug under these conditions in the absence of topo II␣ expression. Immunocytochemical staining revealed that the induction of amphiphysin I in the cell body and neurite extensions was susceptible to ICRF-193 (not shown). It should be pointed out that those topo II inhibitors with different action mechanisms bring about similar results. ICRF-193 and other bisdioxopiperazines inhibit topo II activity without interfering with the DNA rejoining step but by binding to the closed-clamp form of the enzyme-ATP complex to prevent its conversion to the open-clamp form (38) . Presence of cell lines that are selectively resistant to this class of drugs and express topo II␣ having a point mutation in its ATP-binding site (39) strongly suggests that topo II is the single molecular target of ICRF-193. Also deserve mentioning here is that the cells stayed healthy and viable until the final day in culture in the presence of ICRF-193. Generally, it is much less cytotoxic compared with topo II poisons like etoposide which induce DNA strand breaks. Cytochemical staining of apoptotic cells detected only a low level of apoptosis in both the ICRF-treated and control cultures.
In the experiment shown in Fig. 6 , topo II inhibitors were first added at day 1 and cells were kept exposed to the drugs thereafter by supplementary additions. To see whether the inhibitory effect on amphiphysin I expression depends on the initiation timing of the drug treatment, the addition of ICRF-193 was delayed in order (Fig. 7A) . The efficiency of inhibition decreased successively as the timing of drug addition was delayed. This phenomenon was more clearly illustrated by plotting the starting time of drug treatment against a susceptibil-2 K. Sano, K. Tsutsui, and K. Tsutsui, unpublished observation. ity index which was calculated from the induction rate determined after 1.5 days (Fig. 7B) . These data suggest that topo II␤ activity is involved in an early stage of granule cell differentiation in vitro that potentiates the induction process of amphiphysin I. Topo II␤ activity appears to be essential for this stage to initiate since even in cells cultured for 4.5 days in the presence of ICRF-193, amphiphysin I was induced at a normal rate upon removal of the drug (Fig. 7A, f) .
The induction of amphiphysin I protein was reflected by the mRNA contents as estimated by Northern blotting (Fig. 8A) . The amphiphysin I transcript was also decreased by ICRF-193 to a similar extent as in the protein level, suggesting that the effects of topo II inhibitors on protein amounts are not due to a decreased rate of translation or an accelerated protein degradation. Effects of ICRF-193 on transcript levels were further analyzed with other gene probes and are also shown in Fig. 8 . All the transcripts were induced as granule cells differentiate in culture. These proteins are directly involved in neuronal functions such as exocytosis (synaptophysin) or endocytosis (amphiphysins I and II) of synaptic vesicles, and a neurotransmitter receptor protein (␥-aminobutyric acid receptor ␣6 subunit). The inducible genes were either susceptible to the drug (Fig. 8, A and B) or not susceptible at all (Fig. 8, C and D) . Genes that are already expressed in vivo at P8 and some housekeeping genes tested so far were not suppressed by ICRF-193 (data not shown). Amphiphysin II is an isoform of amphiphysin I encoded by a distinct gene (37) . They have been suggested to cooperate by forming a heterodimer (40) . Unexpectedly, they behave differently in the presence of the topo II inhibitor (Fig. 8, A and C) . These results from the transcript analysis were confirmed at the protein level by Western blotting.
If the mRNAs for amphiphysin I and synaptophysin are rapidly turning over, the observed susceptibility to ICRF-193 might be caused by a slight decrease in their transcription rates. To see whether or not this is the case, mRNA turnover rates were measured by blocking the RNA polymerase II-dependent transcription with 5,6-dichloro-1-␤-D-ribofuranosylbenzimidazole at an early stage of chain elongation (Fig. 9) . Half-lives were estimated to be 10 and 14.3 h for amphiphysin I and synaptophysin mRNAs, respectively, indicating that both messages are quite stable. Also, ICRF-193 did not facilitate their degradation since the turnover rates remained basically unchanged in its presence. Furthermore, the drug exerted little effect on the transcription initiation of both genes in late stage granule cells, as revealed by a nuclear run-on assay in that the cells at culture day 6 were treated with ICRF-193 for 24 h (not shown). This is also consistent with the results at the protein FIG. 5 . Expression of neurofilaments and topo II isoforms in the cerebellar granule cells differentiating in vitro. Cerebellar tissue from P8 rats was processed for primary culture according to the procedure described under "Experimental Procedures." Granule cells grown on coverslips were fixed at the days indicated with 4% paraformaldehyde and immunostained with antibodies to neurofilament proteins, topo II␣, and topo II␤. level (Fig. 7) . These data suggest that the differential effect of ICRF-193 on mRNA levels is not due to differences in mRNA turnover rates. Therefore, it is most conceivable that the inhibition of topo II␤ activity interferes with some upstream events, resulting in the selective suppression on the transcriptional induction of a subset of inducible genes.
As only a limited number of gene transcripts were analyzed thus far, we finally investigated inducible genes and their ICRF susceptibility using a larger set of identified gene probes that are fixed on membrane as a cDNA macroarray. Out of 300 detectable hybridization signals, 54 (18%) were increased, 36 (12%) were decreased, and 210 (70%) were unchanged during the 5 days in culture. The identity of up-regulated genes were summarized in decreasing order of inducibility (Fig. 10 ). As expected, multiple genes that are required for neuronal functions such as ion channels, receptors, and signal transduction molecules were noticeable in the list. Although showed little effect on majority (96%) of the constitutively expressed genes, one-third of the inducible gene transcripts were repressed by the drug (termed class I genes). In light of these results, we propose that inducible genes can be classified into two groups with respect to their susceptibility to ICRF-193 in vitro. According to this criteria, therefore, amphiphysin I and synaptophysin belong to the class I, and amphiphysin II and ␥-aminobutyric acid receptor ␣6 belong to the class II genes (Fig. 8) . The underlying mechanism for the difference is unclear at present (see "Discussion"). In conclusion, topo II␤ may thus be involved in an early stage of differentiation and regulate the transcriptional induction of a subset of neuronal genes that are to be up-regulated during the course of differentiation.
DISCUSSION
Topo II Isoforms in Differentiating Neuronal Cells Are Catalytically Active in Vivo-Topo II is an enzyme that transiently cleaves DNA double strands in one duplex segment to form an enzyme-operated gate and rejoins the cleaved DNA ends after passing a second double-stranded DNA segment through the gate. This enzymatic activity is essential for the segregation of daughter chromosomes and thus for cell proliferation. Growing evidence supports that the role is exclusively played by topo II␣ in mammalian cells (1) . Our immunohistochemical data showing that topo II␣ in the developing cerebellum localizes predominantly in cells situated in the mitotic zone are consistent with this view. A large proportion of topo II␣ was found in covalent complexes with DNA after the treatment with etoposide, suggesting that topo II␣ expressed in dividing EGL cells is catalytically involved in vivo in proliferative processes such as chromosomal condensation and segregation (41, 42) .
Following the final division cycle and migration in embryonic days, Purkinje cells start to develop dendrites at their final destination beneath the EGL (34) . It is these periods (P1-P5) when the expression of topo II␤ in nucleoplasm of Purkinje cells reaches the highest level. Immunofluorescence and confocal microscopy revealed fine granulo-fibrous or reticulo-punctate localization of topo II␤ throughout the nucleoplasm. Similar nucleoplasmic distribution of topo II␤ was reported in cultured cells such as A431 human epidermoid cells (43) and Chinese hamster ovary fibroblasts (44) . The transient decrease in the total amount of topo II␤ that occurred at around P5 (Fig. 3) may be caused by the declining topo II␤ content in Purkinje cells. At P5, topo II␤ expressed in granule cells seems to contribute only partially to the total enzyme amount. -193 was added at the first, third, and fifth days to ensure continuous treatment. This treatment schedule was adopted to minimize the cytotoxicity of etoposide and maximize the effect of ICRF-193 which was shown to inhibit topo II activity in vitro completely at 10 M (54) and inhibit the growth of U-937 cells for at least 3 days in culture with a single addition at 0.6 M (55). Protein blots were probed with a human autoantibody against amphiphysin I. Immunoreactive bands on the membrane (shown below the graph) were scanned and quantified by densitometry. As upper bands of the doublet were identified as a phosphorylated form of amphiphysin I, they were also included into the calculation. Data points were normalized by the total protein amounts loaded onto the gel and expressed as induction folds relative to day 1.
FIG. 7. Effects of delayed addition or removal of ICRF-193 on the amphiphysin I induction.
A, amphiphysin levels were analyzed as described in the legend to Fig. 6 . No drug control (a); 10 M ICRF-193 was added daily starting from the culture days 0.5 (b), 2.5 (c), 4.5 (d), and 6.5 (e). In f, cells were treated with the drug as in b until day 4.5 when the medium was replaced with drug-free medium. B, ICRF susceptibility of the amphiphysin induction was calculated by {1 Ϫ (increment during 1.5 days in culture with drug)/(increment during 1.5 days in culture without drug)} ϫ 100, and plotted against the starting time of the drug treatment. One-hundred % susceptibility indicates complete repression of the amphiphysin induction during the first 1.5 days in the presence of Granule cells start to differentiate in the inner zone of EGL (differentiating zone) soon after their final division in the mitotic zone of EGL. The granule cell differentiation is most active around 10 days after birth (34) . The expression of topo II␤ in the nucleoplasm follows a similar time course and so does the immunoreactive material recovered from the CsCl gradient (Fig. 3) . Intranuclear localization of topo II␤ showed a fine granulo-fibrous pattern as seen in the differentiating Purkinje cells. In both Purkinje cells and granule cells, therefore, intensity of topo II␤ staining in the nucleoplasm increased as cellular differentiation proceeds, reaching a maximal level when the cells are most actively involved in differentiation. At the peak of granule cell differentiation, about a quarter of total topo II␤ was recovered as topo II-DNA covalent complexes after treating the cerebellar tissue with etoposide. This is a clear indication of topo II␤ being actively engaged in its catalytic reaction in the differentiating neuronal cells. Since the gene expression in developing cerebellum is strictly controlled in a temporospatial manner (45) , one can speculate that topo II␤ in differentiating neurons might be a part of machinery that controls gene expression according to the developmental program, probably through altering the superstructure of genomic DNA. As the cerebellar architecture came close to its fully developed adult form toward the end of the third week, the catalytically competent topo II␤ decreased gradually to reach a detection limit and the nucleoplasmic topo II␤ in granule cells also decreased while the staining of nucleolus-like structures remained unchanged. Their identity as nucleoli has been demonstrated by double immunostaining of antigens that are known to localize in nucleolus. 3 Expressed level of topo II␤ protein also decreased in the third postnatal week, but the decrease leveled off at about half the maximum level. These results imply that the topo II␤ in nucleoplasm is the catalytically competent entity that is actively involved in the neuronal differentiation and disappears once neurons are terminally differentiated. The residual topo II␤ in the terminally differentiated neurons that localizes mainly in nucleoli is likely to be inaccessible to chromatin DNA although it is still active on naked DNA in vitro (16) .
Functional Topo II␤ May be Required for the Induction of a Subset of Neuronal Genes-Topo II-specific inhibitors have been used in various cell systems to investigate the involvement of topo II in cell differentiation. However, the results from these studies, especially those done in early times without knowing the presence of isoforms, are difficult to interpret. Additional ambiguity originates from the fact that usually both topo II isoforms are expressed in cultured cells and they are both susceptible to such inhibitors. This makes it unable to assess which enzyme is responsible for modulated gene expression although levels of topo II␣ and topo II␤ can be estimated separately using isoform-specific antibodies. For instance, etoposide was shown to induce the differentiation of human promonocytic leukemia U-937 cells as revealed by an increase in the production of reactive oxygen species and surface expression of differentiation-specific antigens (46) . It was also shown that the cells treated with etoposide were arrested at the G 2 phase and ceased to proliferate. It appears, therefore, that the observed alteration in gene expression is attributable to the growth arrest caused by inhibition of topo II␣ and similar effects may be expected when etoposide is replaced with mitotic inhibitors such as mitomycin C (47) . Topo II␤ may have some action points in differentiation pathways downstream the growth arrest but it is difficult to prove this because of the inherent experimental drawback mentioned above. The same situation applies to other studies using topo II inhibitors in differentiating culture cells (48, 49) .
Our experimental system, primary culture of cerebellar granule cells, reflects an ongoing process of in vivo differentiation and is clearly advantageous over cultured cell lines that are forced to differentiate by addition of inducers. In the granule cell culture majority of cells that can be maintained in vitro are derived from the postmitotic neurons in EGL and possibly in ML but the cells in GL do not survive at all (50) . Because of this selection, the culture starts with largely immature granule cells and their differentiation proceeds semi-synchronously. The present study demonstrates that the transcriptional induction of a number of genes is markedly repressed by topo II inhibitors (termed class I genes). The effect is caused neither by inhibition of topo II␣ which is not expressed in these cells nor by inhibition of general transcription as supported by the predominance of class II genes and many other genes that are constitutively expressed and not susceptible to ICRF-193. The incomplete inhibition of class I genes may be explained by a subtle difference in the timing between the onset of induction and the addition of topo II inhibitors. As substantial topo II␤ expression is already present in many cells at day 1 (Fig. 5) , the putative process requiring topo II␤ activity might have been partially completed when inhibitors were added, being consistent with the result that ICRF-193 exerted less effect on the amphiphysin I induction when the addition was further delayed (Fig. 7) . The result also implies that the action point of the drug is not in the transcription per se which is still active in the later stages of differentiation and should be equally susceptible to the drug. These observations are consistent with the involvement of topo II␤ in early processes of granule cell differentiation when class I genes are likely to be potentiated for transcription. The potentiation step for class II genes is either completed already in vivo or not required at all for their transcriptional activation. To our knowledge these results are the first unequivocal implication that catalytically competent topo II␤ is required for a transcriptional regulation of differentiation-related genes. Attempts to clarify the molecular mechanisms underlying these processes are in progress.
Our study also corroborates a probable link between topo II␤ and embryonic neural development in light of the recent report on a gene disruption mutant for topo II␤ (24) . The top2␤ Ϫ/Ϫ mouse embryos show no apparent defect in neurogenesis and overall growth until E15.5. At E18.5, however, normal innervation pattern of the diaphragm and limb muscles is absent in that motor neuron axons fail to branch and contact muscle fibers. Development of sensory axons in the spinal cord is also defective in the top2␤ Ϫ/Ϫ embryos. It is interesting to note that the mutation affects only late stages of embryogenesis and not all the neural developments are involved since the growth of motor axons is not impaired in the intercostal muscles. Therefore, topo II␤ is not a general but rather a specialized factor that is essential for neuronal differentiation. This view is consistent with our results that induction of only a subset of genes is interfered by topo II inhibitors in the granule cell culture. The mutant mice die shortly after birth and it is not feasible to analyze the postnatal events including cerebellar development. Unfortunately, abnormalities in the central nervous system of the top2␤ Ϫ/Ϫ embryos have not been assessed in detail. The absence of topo II␤ may as well affect the early development of the Purkinje cell lineage occurring around E15, as we have observed a concomitant induction of topo II␤ and calbindin, a marker protein for Purkinje cells, in the postmitotic progenitor cells. 3 Possible Mechanisms for the Topo II␤-mediated Gene Regulation-We have shown in the present study that the nucleoplasmic topo II␤ is actively involved in DNA transactions underlying the granule cell differentiation that accompany activations of gene expression. Induction of developmentally regulated genes like the ␤-globin gene cluster is believed to proceed in two steps (51) . Prior to the transcriptional activation enabled by specific interactions between regulatory cis elements and trans-acting protein factors, chromatin conformation of the gene-containing region must be modified to a less condensed state to ensure such interactions (gene potentiation). Although there have been no direct evidence for chromatin decondensation catalyzed by topo II␤, the decondensation of sperm head chromatin in Xenopus egg interphase extract was shown to be inhibited by . It is quite possible that topo II␤ assists the decondensation of chromatin which is essential for some genes to be expressed according to the developmental program.
In eukaryotes, particular genomic segments called matrix attachment regions organize the genome into large looped domains that are topologically independent. We have demonstrated recently that the putative action sites of topo II␤ in the P10 rat cerebellum are predominantly AT-rich noncoding se- Three RNA preparations were isolated from untreated granule cells at day 1, at day 5, and ICRF-treated cells at day 5, respectively. Relative levels of specific transcripts in these preparations were determined by hybridization to a cDNA macroarray. Gene transcripts that displayed 2-fold or greater changes were scored as significant changes. Only 36 induced genes are shown here with GenBank TM accession number, protein identity, induction fold, and the ICRF-inhibition index defined as {(signal increment during 5 days in culture with drug)/(signal increment during 5 days in culture without drug)} ϫ 100. The inducible genes were sorted into two groups with different susceptibilities to ICRF-193 by applying preset thresholds for the ICRF-inhibition index: less than 50% (class I genes), and between 70 and 130% (class II genes).
quences frequently associated with matrix attachment regions. 4 Topological effects exerted by topo II␤ acting on matrix attachment regions can be propagated throughout the whole loop. We also found that the average nuclear volume of granule cells increases by 30% after 7 days in culture (results not shown). Nuclear size of nondividing cells is generally correlated with the state of chromatin condensation and the differentiating granule cells indeed showed more dispersed chromatin when DNA was stained with Hoechst 33342. Decondensation of chromatin have also been noticed in the maturation process of granule cells observed in tissue sections (34) . As expected, the nuclear enlargement in vitro was suppressed by ICRF-193. Therefore, topo II␤ appears to modulate the superstructure of chromatin in a detectable scale. This may involve the nucleosomal structure as well, because a recent study showed that Drosophila topo II is a component of a chromatin-remodeling factor designated CHRAC (53) . Connection between the chromatin decondensation and the transcriptional induction of specified genes will be demonstrated by further analysis including the detection of altered chromatin conformation and detailed mapping of topo II␤ target sites within the class I gene. These experiments will reveal the local environment of individual genes and also clarify the reason why the induction of class II genes is independent of topo II␤ activity.
